Crossmark

An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologies

Crossref DOI link: https://doi.org/10.1186/s12913-019-3914-7

Published Online: 2019-02-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Incerti, Devin http://orcid.org/0000-0002-4479-8750
Browne, John

Huber, Caroline

Baker, Christine L.

Makinson, Geoff

Goren, Amir

Willke, Richard

Stevens, Warren
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2019-02-11
More Information

Article History

Received: 7 March 2018

Accepted: 17 January 2019

First Online: 11 February 2019

Ethics approval and consent to participate

: Not Applicable.

: Not Applicable.

: The following author(s) were employees and stockholders of the sponsor: CL Baker and G Makinson. D Incerti, and C Huber are employees of Precision Health Economics. W Stevens is an employee of Parexel International. J Browne is an employee of University College Cork. A Goren was an employee of Kantar Health at the time of study conduct. R Willke is an employee of the International Society for Pharmacoeconomics and Outcomes Research. Precision Health Economics received funding from Pfizer for conducting this study and for the development of this manuscript. Kantar Health received funding from Pfizer for consultation on this study and for the development of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.